The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Thiazolidinediones
Abstract
Despite a large need for new hypoglycemic therapies, given the epidemic of type 2 diabetes, very few agents have been introduced during the past 20 years. The thiazolidinediones represent a potentially important new group of drugs with a mechanism of action differing from and perhaps complementary to that of existing therapies. This article discusses present data on mechanisms, indications, and limitations of thiazolidinedione therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These actions modulate the transcription of genes with favorable effects on insulin sensitivity,13,36 fat distribution,37 plasma glucose,35,38 lipid and protein metabolism,36,38 vascular endothelial function,39 and inflammation.35,40”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [35]
In the citing paper
“Pioglitazone activates PPAR-γ and also causes partial activation of PPAR-α.35”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [35]
In the citing paper
“Thiazolidinediones (TZDs or glitazones) are peroxisome proliferator–activated receptor γ modulators; they increase the sensitivity of muscle, fat, and liver to endogenous and exogenous insulin (“insulin sensitizers”) (31).”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [31]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients
Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K., et al. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.6.1595 · Cited by 3,133
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Research works printed but not linked: 3
- Yki-Järvinen H. Insulin resistance in type 2 diabetes. In: Pickup JC, Williams G, eds. Textbook of diabetes. 3rd ed. Oxford, England: Blackwell, 2003:22.1-22.19.
- 10.1111/j.1572-0241.2003.07486.x · doi:10.1111/j.1572-0241.2003.07486.x · Paper page
- Charbonnel B, 2002, Diabetologia, 45, A107
Cited by
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Metadata
- Authors
- Yki-Järvinen, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-09-09
- Volume
- 351
- Issue
- 11
- Pages
- 1106-1118
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4240449862
- Cited by
- 1,830
- References
- 110
- Citations by year
- 2026: 26 · 2025: 33 · 2024: 41 · 2023: 45 · 2022: 57 · 2021: 60 · 2020: 55 · 2019: 53 · 2018: 74 · 2017: 74 · 2016: 65 · 2015: 76 · 2014: 75 · 2013: 94 · 2012: 108
- FWCI
- 19.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- thiazolidinediones, type 2 diabetes, hypoglycemic therapy, mechanism of action, antidiabetic drugs, drug indications, drug limitations
- MeSH terms
- Adipose Tissue, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fatty Liver, Female, Gene Expression Regulation, Humans, Hypoglycemic Agents, Insulin Resistance, Lipodystrophy, Polycystic Ovary Syndrome, Risk Factors, Transcription Factors, Biomarkers, Receptors, Cytoplasmic and Nuclear, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thiazolidinediones. https://app.cochat.ai/papers/10.1056/nejmra041001
- The paper
- Yki-Järvinen, H. (2004). Thiazolidinediones. New England Journal of Medicine. https://doi.org/10.1056/nejmra041001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.